VYNE Therapeutics (NASDAQ:VYNE) Earns Buy Rating from Analysts at BTIG Research

BTIG Research began coverage on shares of VYNE Therapeutics (NASDAQ:VYNE) in a research note issued to investors on Monday morning, MarketBeat.com reports. The firm issued a buy rating and a $8.00 price objective on the stock.

Separately, HC Wainwright reissued a “buy” rating and set a $5.75 target price on shares of VYNE Therapeutics in a research note on Friday, November 8th.

VYNE Therapeutics Stock Performance

Shares of NASDAQ VYNE opened at $2.72 on Monday. VYNE Therapeutics has a fifty-two week low of $1.57 and a fifty-two week high of $4.24. The company has a market cap of $40.12 million, a price-to-earnings ratio of -3.16 and a beta of 1.32. The business’s 50 day moving average price is $2.29 and its 200-day moving average price is $2.19.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in VYNE Therapeutics stock. Lynx1 Capital Management LP bought a new position in VYNE Therapeutics Inc. (NASDAQ:VYNE) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 16,194 shares of the company’s stock, valued at approximately $32,000. VYNE Therapeutics accounts for 0.0% of Lynx1 Capital Management LP’s holdings, making the stock its 17th biggest holding. Lynx1 Capital Management LP owned 0.11% of VYNE Therapeutics at the end of the most recent reporting period. Institutional investors own 83.78% of the company’s stock.

VYNE Therapeutics Company Profile

VYNE Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing proprietary and therapeutics for the treatment of immuno-inflammatory conditions. The company's lead product is VYN201, a locally administered pan- bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways with low systemic exposure.